{
    "nct_id": "NCT05736419",
    "official_title": "Pre-Transplant Immune Suppression With Hematopoietic Cell Transplantation From Haploidentical Donors for Adults and Children With Sickle Cell Disease or ß-Thalassemia (Haplo PTCy)",
    "inclusion_criteria": "* Age > 12 and < 35 years. Patients of age 2-12 and 35-50 years will be included after 8 patients reach day 100 without TRM and if ≥ 4 of the first 8 patients reach day 100 without graft failure or grade III-IV acute GvHD.\n* Suitable haploidentical donor.\n* Performance score ≥ 70% by Karnofsky Performance Scale or 0 to 1 by ECOG (age > 16 years), or Lansky Play-Performance Scale ≥ 70% (age ≤ 16 years).\n* Adequate major organ system function as demonstrated by:\n\n  * For patients ≥ 18 years of age:\n  * eGFR ≥ 50 mL/min by Cockcroft-Gault formula\n  * For patients < 18 years of age:\n  * Serum creatinine clearance: glomerular filtration rate [GFR]) must be >50 mL/min/1.73 m2 as calculated by the Schwartz formula\n* Conjugated (direct) bilirubin less than 2x upper limit of normal.\n* ALT or AST ≤ 3 times institutional upper limit of normal.\n* Left ventricular ejection fraction ≥ 50%.\n* Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted, corrected for hemoglobin. For children < 7 years of age who are unable to perform PFT, oxygen saturation > 92% on room air by pulse oximetry.\n* For SCD patients: HbSS, HbSC, HbS/β° with one or more of the following complications:\n\n  * Acute chest syndrome: 2 or more episodes in the 2 years preceding enrollment\n  * Vaso-occlusive episodes: 3 or more episodes in the 2 years preceding enrollment\n  * Recurrent priapism: 2 or more episodes in the 2 years preceding enrollment\n  * History of osteomyelitis or osteonecrosis\n  * Cerebrovascular disease:\n* Imaging evidence of prior overt or silent stroke\n* History of a neurologic event resulting in focal neurologic deficits lasting > 24 hours\n* Abnormal transcranial Doppler: Timed average maximum mean velocity ≥ 200 cm/sec in terminal portion of the carotid or proximal portion of the middle cerebral artery or > 185 cm/sec plus evidence of intracranial vasculopathy if imaging TCD is used\n\n  * Pulmonary hypertension: Confirmed by right heart catheterization with mean pulmonary arterial pressure ≥ 25 mmHg or mean pulmonary vascular resistance > 2 Wood units\n  * Red blood cell alloimmunization (> 3 alloantibodies)\n* For thalassemia patients: Any genotype, with all of the following:\n\n  * Onset of red blood cell transfusion dependence during the first 3 years of life\n  * RBC transfusion history > 225 mL/kg/year or > 15 lifetime RBC transfusions\n  * Pre-transfusion hemoglobin ≤ 7 g/dL\n  * Hepatosplenomegaly\n* Patient or the patient's legal representative, parent(s) or guardian should be able to provide written informed consent. Assent of a minor if participant's age is at least seven and less than eighteen years.\n* For sexually active men and women of childbearing potential, must agree to use a form of contraception considered effective and medically acceptable by the Investigator.\nHealthy volunteers allowed\nMust have minimum age of 2 Years\nMust have maximum age of 50 Years",
    "exclusion_criteria": "* Prior myeloablative allogeneic HCT.\n* Overt stroke or CNS instrumentation (e.g. for Moyamoya disease) within 6 months of enrollment.\n* Liver cirrhosis. Mild fibrosis will be permitted, i.e. fine reticulin or grade 1 of 4, with bridging fibrosis.\n* Hepatic iron content ≥ 3 mg Fe/g liver dry weight\n* HIV positive\n* Active hepatitis B or C.\n* Other uncontrolled infections.\n* BMI > 40.\n* Other malignancy/cancer diagnosis unless in remission after definitive therapy for a minimum of 2 years. Exceptions: Ductal carcinoma in situ, basal cell carcinoma, cervical intraepithelial neoplasia.\n* Positive pregnancy test in a woman with child-bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization.\n* Inability to comply with medical therapy or follow-up.\n* Known history of allergic reactions to any constituents of the cell product, including a known history of allergic reactions to DMSO.",
    "miscellaneous_criteria": ""
}